Related Experiment Videos
beta tubulin mutations are rare in human ovarian carcinoma
Diana E Lamendola1, Zhenfeng Duan, Richard T Penson
1Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA 02114, USA.
Background:
The interaction between paclitaxel and its target, beta tubulin, is essential for effective cytotoxicity. Alterations or mutation of beta tubulin have the potential to alter paclitaxel binding and confer a drug resistant phenotype.
Materials And Methods:
Twenty-nine paired tumor samples from women with ovarian cancer were examined to evaluate the incidence of exon four mutations in tumors with evolving paclitaxel resistance. Tissue was dissected from five-micron paraffin slices and analyzed for mutations in exon four of human beta tubulin by PCR-SSCP. Nested PCR primers generated three partially overlapping or neighboring fragments corresponding to exon four of beta tubulin. 32P labeled PCR fragments were then subjected to SSCP analysis polyacrylamide gel electrophoresis.
Results:
PCR-SSCP analysis demonstrated no mutations in the twenty-nine paired tumor samples studied.
Conclusion:
This result suggests that mutations within exon four of human beta tubulin are rare in newly-diagnosed and recurrent paclitaxel resistant human ovarian cancer.
Insights
Paclitaxel resistance in ovarian cancer is not typically caused by mutations in beta tubulin exon 4. This study found no such mutations in patients with newly-diagnosed or recurrent tumors.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Paclitaxel's cytotoxicity relies on its interaction with beta tubulin.
- Beta tubulin mutations can lead to paclitaxel resistance.
Purpose of the Study:
- To investigate the incidence of beta tubulin exon 4 mutations in paclitaxel-resistant ovarian cancer.
- To determine if these mutations contribute to drug resistance phenotypes.
Main Methods:
- Analysis of 29 paired ovarian tumor samples using PCR-SSCP.
- Focus on exon 4 of human beta tubulin for mutation detection.
- Utilized nested PCR and polyacrylamide gel electrophoresis.
Main Results:
- No mutations were detected in exon 4 of beta tubulin across all 29 tumor samples.
- PCR-SSCP analysis confirmed the absence of targeted mutations.
Conclusions:
- Mutations in beta tubulin exon 4 appear to be rare in paclitaxel-resistant ovarian cancer.
- This suggests alternative mechanisms may drive paclitaxel resistance in this patient population.